K
etamine is an IV anesthetic with analgesic properties in subanesthetic doses (1) (2) (3) (4) (5) . Interest in the analgesic properties of small-dose ketamine has prompted clinical trials comparing opioids and ketamine. The results of these trials have shown that analgesia produced by ketamine alone was not equivalent to that produced by opioid analgesics (6 -9) . However, recognition of its actions on N-methyl-daspartate (NMDA) receptors renewed clinical interest in ketamine as a perioperative analgesic. Strong pain stimuli activate NMDA receptors and produce hyperexcitability of dorsal root neurons. This induces central sensitization, wind-up phenomenon, and pain memory. Ketamine, a noncompetitive antagonist of NMDA receptors, can prevent the induction of central sensitization caused by stimulation of peripheral nociception as well as blocking the wind-up phenomenon (10) . It has also been reported that receptor activation by opioids leads to a sustained increase in glutamate synaptic effectiveness at the level of NMDA receptors. Opioids when used alone in large doses for a prolonged period induce tolerance, which may lead to increased postoperative pain (11) . Ketamine, by blocking these NMDA receptors, can prevent the development of tolerance. This has been studied extensively in animals and consistently produced positive results (12) (13) (14) (15) . This concept was the basis for multiple clinical trials involving ketamine as an adjuvant to opioids and multimodal analgesia. Contrary to the experimental evidence, clinical trials in humans have shown mixed results. We performed a qualitative and quantitative systematic review of randomized, double-blind clinical trials of ketamine added to opioid analgesia to provide a reasonable answer to this controversy.
databases without language restriction. Abstracts, letters of correspondence, and unpublished observations were not considered for the review.
The following search terms were used: ketamine, morphine, fentanyl, alfentanil, sufentanil, remifentanil, ketamine with morphine, ketamine with opioid, ketamine and morphine, postoperative analgesia, postoperative pain relief, postoperative pain, opioid tolerance, and multimodal analgesia. Lists of references of individual articles and review articles were also searched for additional relevant articles. Authors were contacted for the missing information on methods such as randomization and blinding or for original data such as pain scores if necessary.
Two authors read all selected articles independently and consensus was subsequently achieved. Studies were considered for this review if they compared two groups, one group with opioid analgesia and another group with ketamine added to opioid analgesia. Type of opioid administered was noted but studies involving all opioids (meperidine, morphine, fentanyl, alfentanil, sufentanil, and remifentanil) were considered. Route (IV, IM, subcutaneous [SC] , and epidural) and dose of opioid should have been similar in both groups. Route (IV, IM, SC, and epidural), method (single bolus, infusion, and patient-controlled analgesia [PCA]), and timing of administration of opioid and ketamine (postoperative, preoperative) were noted.
Studies comparing preincisional versus postincisional administration of ketamine alone (16 -18) or in combination with opioids (19 -22) were excluded. Studies comparing "opioids" with "ketamine as a sole analgesic" were not considered. Studies involving another class of analgesics along with opioids and ketamine, if common to both groups (local anesthetics, nonsteroidal antiinflammatory drugs [NSAIDs] , clonidine, and neostigmine) were noted but not excluded.
Each report that met the inclusion criteria was scored using a 3 item, 1-5 score quality scale (23) . If the study was described as randomized, one point was given and an additional point was given if the method of randomization was described and considered adequate (e.g., computer-generated, table of random numbers). For trials described as double-blind, one point was given. An additional point was given if the method of blinding was described and considered adequate. Finally, reports that described the numbers and reasons for withdrawal were given one point. By definition, studies without randomization and blinding were excluded. Thus, the minimum score of an included trial was 2 and maximum score was 5. Trials with sample size Ͻ10 were not considered (24) .
The following data were obtained from all included studies: number of patients, grouping of patients, ASA physical status, power calculation for sample size, type of surgery, intraoperative analgesics used, route (IV, epidural, intrathecal, and oral), dose and method (bolus, infusion, or PCA device) of administration of opioid and ketamine, other analgesics used, and duration of observation.
The postoperative analgesia outcome measures (pain scores, time to first requirement for analgesia (TFA) and total supplemental analgesic requirement (TSD)) for the first 24 h were noted for analysis.
The following adverse effects were noted for analysis: postoperative nausea and vomiting (PONV), sedation, respiratory depression, pruritus, and central nervous system (CNS) side effects (dizziness, disorientation, dysphoria, confusion, excessive sedation, bad dreams, strange feelings, and hallucinations).
Trials were stratified according to the route (epidural, IV) and method (infusion, bolus) of ketamine administration. Studies on pediatric patients were considered separately. Visual analog score (VAS, 0 -100 mm, 0 ϭ no pain and 100 ϭ maximum pain), as pain outcome measure, was quantitatively analyzed. Verbal rating pain score (VRS, 0 -100 mm), numeric rating score, and similar scores were converted to VAS pain scores (e.g., a 4-point VRS including no, mild, moderate, and severe pain was converted to 0, 25, 50, and 75 mm VAS respectively) for analysis. Mean VAS for each treatment group was determined for each trial from all available observations within 24 h after surgery. Quantitative analysis of combined VAS data from different studies over 24 h was performed using Review Manger 4.2. (Review Manager, Version 4.2; the Cochrane collaboration, The Nordic Cochrane center, Copenhagen, Denmark). Weighted mean difference (WMD) for VAS between the two treatment groups was calculated for each study and combined data. The weight given to each study was determined by the sample size and standard deviation of VAS scores in individual trials.
Qualitative evaluation of postoperative analgesic efficacy was done using significant differences (P Ͻ 0.05 as reported in the original articles) in pain scores, TFA, and TSD between the two groups.
Adverse effects such as CNS side effects, PONV, pruritus, and respiratory depression were quantitatively analyzed after summation of events from all studies. Relative risk (RR) was considered statistically significant when the 95% confidence interval (CI) did not include 1.
Results
Thirty-seven trials with 51 treatment arms were included for analysis (Tables 1-6 ). A total of 2385 patients were studied, of whom 1336 received ketamine. Intravenous ketamine was administered as a bolus in 11, as an infusion in 11, and as IV PCA in 6 clinical trials. Epidural ketamine was studied as an adjuvant to epidural opioids in 8 trials. Twenty trials reported improvement in analgesia with the addition of ketamine to opioids whereas 17 trials did not find significant clinical benefit. Average quality score was 4.1 for both negative and positive clinical trials. No significant correlation was detected between the timing of ketamine administration and its analgesic efficacy. Ketamine was given before incision in 52% of the C ϭ control (opioids only group); K ϭ ketamine group; PCA ϭ patient-controlled analgesia; TFA ϭ time to first request for analgesia; TSD ϭ total supplemental analgesic requirement; PONV ϭ postoperative nausea and vomiting; Preop ϭ before surgery; Intraop ϭ during surgery; Postop ϭ after surgery; NS ϭ no significant difference between the groups.
P values indicate beneficial effects for ketamine group unless otherwise indicated.
positive studies and in 60% of negative studies. Three studies were not suitable for analysis and were excluded: in one study, the number of patients was Ͻ10 (25), in another, patients in both groups received ketamine in the perioperative period (26) , and in a third study, the patients were not randomized (27) . Quantitative analysis was performed on mean VAS pain scores recorded within 24 h after surgery and for adverse events (PONV, CNS side effects, pruritus, and respiratory depression) for ketamine treatment and controls. Data on analgesic consumption, TFA allowed a qualitative analysis because of the variety of analgesics, doses, and outcome reporting were used. Statistical difference between ketamine treatment and control regarding these measures was extracted from original reports and documented (Tables 1-6 ).
Six trials (28 -33) compared IV PCA using the combination of morphine and ketamine with morphine alone (Table 1) . These involved 330 patients, of whom 170 received ketamine with morphine IV PCA. Five trials noted no significant improvement in analgesia, with no significant differences in pain scores or total morphine consumption between the groups (28 -32) . Only one trial (33) in lumbar microdiscectomy showed a clear advantage for adding ketamine with reduction of pain scores, analgesic supplements, and adverse effects of opioids. The quality score of this positive study was 3; whereas the average quality score for negatively reported trials was 4.4.
Mean resting VAS for the first 24 h was analyzed with available data from 5 studies. Test for heterogeneity was significant, giving a random effects model. Overall WMD of Ϫ5.4 mm (95% CI, Ϫ1.26, 0.18) for VAS at rest was statistically not significant between the groups (Fig. 1) . Three trials had VAS scores Ͻ2 (29, 31, 32) . Two negative clinical trials mentioned power calculation based on VAS scores. VAS during movement was mentioned in 3 trials (28, 29, 31) . A WMD for VAS of Ϫ2.7 mm (95% CI, Ϫ0.98, 0.44) was not significant.
Adverse effects (dreams, disorientation, dysphoria, and psychomimetic effects) were increased in ketaminetreated patients in two studies. Reeves et al. (28) reported RR for vivid dreams and hallucinations of 1.8 and 1.3, respectively, in ketamine-treated patients. Burstal et al. (31) noted discontinuing PCA in 4 of 37 patients who received ketamine because of dysphoria. However, CNS side effects analyzed for pooled data from all studies did not reveal any significant differences (27 of 146 (18%) in ketamine plus morphine versus 20 of 135 (15%) in morphine PCA groups (P ϭ 0.31; RR, 1.27; 95% CI, 0.80, 2.01) ( Table 7) . PONV was reduced with ketamine in two studies (29, 33) . Pruritus was significantly less in patients treated with ketamine in two studies (30, 33) . Respiratory depression was noted in 2 patients of Reeves et al. (28) . One of them received ketamine. In one study, ketaminetreated patients were less sleepy (29) whereas other studies did not show any significant effect of ketamine on sedation.
Overall, adding ketamine to morphine in IV PCA is not beneficial in improving the quality of postoperative analgesia, although side effects were not increased by the addition of ketamine.
Seven trials with nine treatment arms were identified using ketamine as a continuous infusion, in addition to IV opioids, in the perioperative period (34 -40) ( Table 2) . Two-hundred-eighty-nine patients were studied; 149 patients received ketamine infusion. Four studies (35, 36, 38, 40) reported significantly improved analgesia with an average quality score of 4. Three studies (34, 37, 39) reported no difference with an average quality score of 3.3. C ϭ control (opioids only group); K ϭ ketamine group; TSD ϭ total supplemental analgesic requirement; NS ϭ no significant difference between the groups; Preop ϭ before surgery; Intraop ϭ during surgery; Postop ϭ after surgery; Gp 1 ϭ Group 1; Gp 2 ϭ Group 2.
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In a dose response study, Edwards et al. (34) did not find a significant decrease in pain scores or analgesic consumption with 5, 10, or 20 mg/h ketamine infusions although adverse events such as dreaming increased with increasing infusion rate.
Stubhaug et al. (35) reported short lasting benefit of ketamine in the early postoperative period (decreased VAS for 1 h, longer TFA, and decreased morphine consumption for 4 h). The main conclusion of their study was that areas of punctuate hyperalgesia and numbers of patients with wind-up pain were significantly reduced by ketamine infusion. There was no correlation with the degree of pain or morphine consumption.
Quantitative analysis of mean VAS at rest for 24 h was performed with available data from 6 studies and 8 treatment arms. One study did not report actual VAS scores (38) . In another trial (34), 5-point VRS (no pain, mild, moderate, severe, very severe) was converted to VAS of 0, 25, 50, 75, and 100 mm respectively. A random effects model was used because the test for heterogeneity was significant. WMD for VAS was Ϫ8.2 mm (95% CI, Ϫ1.51, Ϫ0.14) with beneficial effect for the ketamine infusion groups (Fig. 2) . Two studies had VAS less than 3 in both groups (37, 40) . VAS with movement was reported in two trials, with no significant differences between the groups (39, 40) . Power analysis for reduction of morphine consumption was performed in 5 of 7 trials.
CNS side effects (diplopia, dreams, dizziness, dysphoria) were not significantly increased (P ϭ 0.09) with IV ketamine infusion (15 of 149 (10%) in C ϭ control (opioids only group); K ϭ ketamine group; TFA ϭ time to first request for analgesia; TSD ϭ total supplemental analgesic requirement; NS ϭ no significant difference between the groups, Preop ϭ before surgery; Intraop ϭ during surgery; Postop ϭ after surgery; Gp1 ϭ Group 1; Gp2 ϭ Group 2; PONV ϭ postoperative nausea and vomiting.
P values indicate beneficial effects for ketamine group unless otherwise indicated. C ϭ control (opioids only group); K ϭ ketamine group; PCEA ϭ patient-controlled epidural analgesia; TFA ϭ time to first request for analgesia; TSD ϭ total supplemental analgesic requirement; NS ϭ no significant difference between the groups; Preop ϭ before surgery; Intraop ϭ during surgery; Postop ϭ after surgery.
P values indicate beneficial effects for ketamine group unless otherwise indicated. C ϭ control (opioids only group); K ϭ ketamine group; PCEA ϭ patient-controlled epidural analgesia; TFA ϭ time to first request for analgesia; TSD ϭ total supplemental analgesic requirement; NS ϭ no significant difference between the groups; Preop ϭ before surgery; Postop ϭ after surgery; IV ϭ intravenous; IM ϭ intramuscular; Gp 1 ϭ Group 1; Gp 2 ϭ group 2.
ketamine-treated patients versus 9 of 140 (6.4%) in patients treated with only opioids (RR, 1.31; 95% CI, 0.57, 3.00) ( Table 7 ). Five of the 15 patients who experienced dreams received the most rapid infusion rate (20 mg/h) of ketamine in Edwards et al. 's study (34) . PONV data were available in 5 trials (Table 8) . Combining the data from these studies, no significant differences were found between the groups, though there was a trend towards less PONV in ketaminetreated patients ( in patients who received opioids only; RR, 0.58; 95% CI, 0.33, 1.02; P ϭ 0.06).
One patient in the ketamine group and two patients in the control group developed pruritus (37, 40) . Hypoventilation and respiratory depression were reported in 3 patients each in ketamine and control groups from 2 studies (34,40). Guignard et al. (38) , found increased sedation for 15 min in the immediate postoperative period and Heinke and Grimm (39) reported longer time to orientation in ketamine group Values are number of patients with side effects/number of patients in the study. RR ϭ relative risk; CI ϭ confidence interval; IV PCA ϭ intravenous patient-controlled analgesia. patients whereas others did not find any significant increase in sedation with ketamine. Intravenous ketamine infusion was given in combination with epidural opioids in 4 studies (41-44) with 5 treatment arms (Table 3) . A total of 213 patients were studied; 115 received ketamine. Two studies noted significant reductions in VAS and postoperative opioid consumption (42, 44) . Wound hyperalgesia was studied in two studies (41,43) ; one reported decreased areas of hyperalgesia (41) . The same study also reported decreased residual pain and decreased need for chronic medications at 2 wk, 1 and 6 mo, and 1 yr. Side effects were reported in three studies (41, 43, 44) . CNS side effects (psychomimetic effects such as hallucinations, diplopia, dreams) were noted in 10.7% (9 of 84) of patients in the ketamine group and 4.4% (3 of 68) in control patients (P ϭ 0.25). Kararmaz et al. (44) noted significant reduction in the incidence of nausea In calculating relative risk and 95% CI, the fixed effects model was used for the IV ketamine continuous infusion and epidural ketamine studies; the random effects model was used for the IV ketamine, single bolus studies.
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and itching with the addition of ketamine whereas others did not find any significant difference. Sedation was increased in two studies with ketamine infusion (43, 44) . In conclusion, of the 4 studies, 2 studies reported beneficial effects of ketamine in acute postoperative pain (42,44) whereas another reported decreased wound hyperalgesia and chronic residual pain (41). Ilkjaer et al. (43) administered epidural morphine in combination with IV ketamine only during the second 24 h after surgery when the intensity of pain had decreased, thus reducing the significance of their negative findings. Overall, continuous IV ketamine infusion produced promising results in 6 of 11 clinical trials in improving perioperative opioid analgesia. The incidence of adverse effects was not increased by the addition of ketamine.
Ketamine was administered as a single IV bolus with IV opioids in 11 clinical trials (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (Table 4) . Sixteen treatment arms with 855 patients were found; 504 patients received ketamine. Seven trials with an average quality score of 4.3 reported a positive influence of adding ketamine on postoperative analgesia (45) (46) (47) (48) 50, 51, 54) . Four clinical trials with an average quality score of 3.5 reported no significant effect of adding ketamine (39, 49, 52, 53) . Two positive trials (46, 47) and one negative trial (52) mentioned power calculations. Three positive reports (46, 48, 54 ) and 2 negative reports (52,53) had mean VAS Ͻ3.
Of the 11 trials, 8 (45,46,48 -52, 54) reported improved VAS scores at some time. Quantitative analysis of VAS at rest over 24 h was performed using a random effect model (test of heterogeneity was significant). The data from all clinical trials (n ϭ 11) with 16 treatment arms were considered for analysis. WMD of Ϫ8.5 mm (CI 95%, Ϫ1.25, Ϫ0.44) was obtained in favor of ketamine coadministration (Fig. 3) . VAS with movement was mentioned in 4 treatment arms in 3 trials. Fixed effects model was used as P value for heterogeneity ϭ 0.32. WMD of Ϫ6.2 mm (95% CI, Ϫ0.83, Ϫ0.41) was obtained in favor of ketamine groups.
Suzuki et al. (45) in a dose response study, used 3 doses of ketamine (50, 75 , and 100 g/kg), in addition to morphine, for outpatient surgery. Patients were followed through phase 2 recovery. They concluded that ketamine doses of 75 and 100 g/kg significantly decreased VAS and supplemental analgesic administration in the postanesthesia care unit.
TFA was reported in 5 clinical trials and was significantly prolonged with ketamine in 4 trials. TSD were reported in 9 trials and were significantly decreased in 6.
Nine percent (38 of 444) of ketamine patients experienced CNS side effects (strange sensation, lightheadedness, dreams, sleep difficulties, and confusion) compared with 5% (16 of 322) of control group patients; this difference was not statistically significant, (P ϭ 0.10; RR, 1.61; 95% CI, 0.91, 2.83) ( Table 7) .
Analysis of combined data on the incidence of PONV revealed that there was a trend towards less PONV in ketamine-treated patients compared with patients who received opioids alone (74 of 416 [18%] versus 75 of 283 [27%] control patients, P ϭ 0.33; RR, 0.76; 95% CI, 0.44, 1.32). Test for heterogeneity was significant (P ϭ 0.02) giving a random effects model (Table 8) .
None of the patients in either group developed respiratory depression or pruritus. Two studies (39, 52) found increased time to eye opening and orientation and one study (50) found increased wakefulness with ketamine. Other trials did not find any significant difference in sedation between the groups. Overall, a single dose of IV ketamine improved postoperative analgesia with opioids. Side effects were not increased by a single bolus IV ketamine.
There were 8 clinical trials (41,54 -60) with 10 treatment arms involving epidural ketamine (Table 5 ). Major intrathoracic and abdominal surgeries were chosen in all 8 trials. A total of 513 patients were studied; 269 patients received ketamine. Five studies reported a positive outcome with ketamine (54 -56,58,59) . The average quality score of positive trials was 4.2. One study reported a statistically significant prolongation in TFA but concluded that this was of no clinical relevance (57) . Two studies reported no improvement of analgesia with the addition of ketamine (41, 60) . The average quality score of the negative trials was 4.3. Preincisional and postincisional epidural ketamine were administered in 2 studies, each as a single bolus, as an adjuvant to epidural morphine (54, (57) (58) (59) . Santawat et al. (60) studied the analgesic efficacy of adding epidural ketamine with both preincisional and postincisional morphine (2 treatment arms). Patientcontrolled epidural analgesia (PCEA) with morphine and ketamine was studied in two clinical trials (55, 56) . De Kock et al. (41) , studied ketamine as part of a balanced multimodal analgesic regimen (epidural sufentanil, bupivacaine, epinephrine, and clonidine with IV alfentanil as a rescue analgesic). Ketamine was administered epidurally as a bolus followed by continuous infusion in two different doses (2 treatment arms) in their study.
Sample size justification was stated in only 2 trials. Six trials reported VAS scores; 4 noted significant decreases in VAS with the addition of ketamine (54 -56,59 ). Four studies noted significant increases in TFA with the addition of ketamine. Supplemental analgesic requirements were reported in all 8 clinical trials; 5 found significant reductions in analgesic requirements.
Quantitative analysis of VAS at rest and with coughing was performed with available data from 7 treatment arms. Because the test for heterogeneity was significant, a random effect model was used. WMD of Ϫ7.1 mm (95% CI, Ϫ1.01, Ϫ0.40) for mean VAS at rest in favor of ketamine group was obtained (Fig. 4) . Five treatment arms had VAS less than 3 (42, 54, 55, 59) . WMD for VAS with movement was not significant between the groups (Fig. 5) .
Psychomimetic effects were seen in 2 of 269 patients treated with ketamine compared with none of 244 patients who did not receive epidural ketamine ( Table 7) .
The incidence of PONV was similar in both groups (70 of 229 [31%] with ketamine versus 76 of 224 [34%] in the control group, P ϭ 0.36; RR, 0.90; 95% CI, 0.73, 1.12) ( Table 8) .
Four studies with five treatment arms reported pruritus. The incidence of pruritus from pooled data was 40.5% (47 of 116) in patients who received ketamine with opioid and 45.6% (52 of 114) of the opioid only group patients (P ϭ 0.51). One patient in Santawat et al. 's study (60) developed respiratory depression in the morphine plus ketamine preincisional group. One clinical trial (58) noticed increased sedation in ketamine group patients whereas others did not find any significant difference in sedation between the groups
In conclusion, epidural ketamine added to various opioid-based perioperative epidural analgesic regimens improved analgesia in 5 of 8 clinical trials with no increase in PONV or ketamine-related psychomimetic side effects.
Four clinical trials (61-64) with 5 treatment arms evaluated ketamine as adjuvant analgesic to opioids in children (Table 6 ). Two-hundred-thirty-two children were studied; 129 received ketamine. The route of ketamine administration varied, with IV ketamine given in 2 studies (63, 64) and caudal (61) and IM ketamine (62) in one each. Two studies reported positive outcomes on postoperative analgesia (61, 62) and 2 other studies reported no improvement in analgesia (63, 64) . The average quality scores of both positive and negative trials were 4.5. One positive trial and one negative trial mentioned power calculations. Different pain scales were used in each study, precluding quantitative analysis. Side effects were not increased by ketamine given as single bolus. Intravenous ketamine continuous infusion was associated with increased CNS side effects in one study (63) . No conclusions can be drawn regarding the use of ketamine as adjuvant analgesic in children.
Discussion
In this systematic review, we sought to analyze clinical trials on the efficacy and safety of adding small dose ketamine to perioperative opioid-based analgesia. To demonstrate analgesic efficacy, we used a combined qualitative and quantitative approach for data from randomized, double-blind clinical trials. Quantitative analysis was possible for VAS scores during the first 24 hours of the postoperative period. This was done to produce a single estimate of the effect of the intervention and to help resolve disparities between conflicting studies. The initial 24 hours was chosen because of the availability of data for most clinical trials, as well as the fact that the intensity of pain is maximal during the early postoperative period. WMD of 8.5, 8.2, and 7.1 mm were found in favor of ketamine co-analgesia for a single IV bolus, continuous IV infusion, and epidural ketamine, respectively. Although these differences are statistically significant, clinical relevance is minimal for this outcome measure taken alone.
The limitations of using WMD of VAS as an outcome measure are as follows: first, some trials did not report the actual VAS data and others did not report the dispersion measures needed for analysis. Second, not all clinical trials reported VAS on movement or during coughing/deep inspiration to calculate WMD. Third, VAS alone may not reflect the efficacy of the intervention because some studies aimed to maintain VAS less than 3-4 by analgesic supplementation at all times. In this case, VAS analysis may not show any difference between groups, but the total dose of supplemental analgesia will reflect the effect of the intervention. Only qualitative analysis was possible for other analgesic outcome measures such as TFA and TSD because of the variety of analgesia and doses used. For this reason, qualitative analysis of VAS and other outcome measures were combined with quantitative VAS analysis to provide a reasonable answer.
Finally, control patients involved in this review were already receiving standard practice analgesia and were not deprived of pain medications, unlike metaanalysis of pain interventions compared with placebo. Thus, WMD of VAS was not able to detect a major difference between groups in this review.
Studies were divided into 5 subgroups based on the route and method of ketamine administration (IV ketamine as a single bolus dose, IV ketamine as a continuous infusion with IV and epidural opioids, IV ketamine with opioid in PCA, epidural ketamine with epidural opioids, and studies in pediatric population).
A significant number of clinical trials (17 of 38, 45%) demonstrated no benefit of adding ketamine to the existing standard practice opioid analgesia. This can be explained by the nature of surgical procedure, the degree of postoperative pain and the method of ketamine administration. In surgical procedures such as appendicectomy (64) , tonsillectomy (63) , laparoscopic surgery (52, 53) , and knee arthroscopy (36) , standard practices with opioids, NSAIDs, and local anesthetic infiltration can provide adequate pain relief, so adding ketamine may not provide any additional benefit. Ketamine should be considered when postoperative pain requires large doses of opioids, such as major abdominal and thoracic surgery. Weinbroum (50) evaluated the role of ketamine in morphine-resistant pain. Patients were selected in the recovery room after morphine was given in adequate doses, but pain was still not controlled. The beneficial opioid-sparing effect was shown in these patients with acute opioid tolerance. Selection of these "difficult to manage" patients and a trial of ketamine may be a useful strategy in postoperative pain management. Another reason for the negative findings could be the method and dose of ketamine administration. Among the various methods of IV ketamine administration, continuous IV infusion of ketamine seems to be most helpful in major abdominal surgical procedures. In contrast to IV infusion, adding ketamine to IV PCA opioids was not helpful in 5 of 6 studies. Patients receiving infusions received relatively larger total doses of ketamine. Maintenance of steady blood levels with the continuous infusions (5-10 mg/h) rather than repeated ultra small dose boluses (1-2 mg) as inpatient-dependent PCA administration may be important when using ketamine as an adjuvant with opioid-based analgesic regimens for postoperative analgesia in abdominal surgery.
Epidural ketamine produced impressive results whether administered as a single dose or as continuous infusion with PCEA. Ketamine is not approved by the Food and Drug Administration for epidural use because of its questionable neurotoxic effects. These have been attributed to the preservative (chlorbutanol); preservative-free ketamine is not available in the United States. De Lima et al. (65) , in reviewing the neural toxicity of ketamine, encouraged the continued study of small doses (in small concentrations) of preservative-free ketamine through the epidural route. De Kock et al. (41) and Xie et al. (54) evaluated the appropriate route for the beneficial effect of ketamine as an additive. De Kock et al. used multimodal continuous epidural analgesia with ketamine, sufentanil, bupivacaine, epinephrine, and clonidine. The most valuable outcome of this study was the improvement in the area of wound hyperalgesia and chronic pain with IV ketamine. No difference was detectable in acute postoperative analgesic outcome measures between IV and epidural ketamine. They concluded that the IV route was the choice for ketamine as part of multimodal epidural analgesia. Aida et al. (42) concluded that using epidural morphine and IV ketamine as a continuous infusion throughout surgery blocks the noxious input at segmental and suprasegmental levels, respectively, and provides effective analgesia and prevents CNS sensitization in patients undergoing gastrectomy. However, this trial did not include epidural morphine with epidural ketamine as another group, as they believed that suprasegmental noxious inputs could only be blocked by IV ketamine. A study by Xie et al. (54) compared single doses of IV and epidural ketamine together with intraoperative IV fentanyl and postoperative PCEA morphine. They found a prolonged half-life, sustained large plasma concentrations, and superior analgesic effects with epidural ketamine. It remains to be seen whether a single dose of epidural ketamine can provide superior or comparable analgesia compared with continuous IV ketamine infusion with less side effects.
Beneficial effects of preemptive ketamine analgesia were based on presumed prevention of central sensitization by NMDA receptors (10) . However, others feel that ketamine will be more effective after sufficient nociceptive stimulation has occurred to open the ligand gated ionic channels of NMDA receptors (66) . In this review, both preincisional and postincisional administration of ketamine were found to be useful as adjuvant to opioids in comparable number of trials.
The effect of adding ketamine to opioids or multimodal analgesic regimens on wound hyperalgesia was tested in four clinical trials (31, 35, 41, 43) . Wound hyperalgesia was evaluated by punctuate mapping with Von Frey hair filaments and pressure pain detection thresholds. The area of hyperalgesia tested by Von Frey hair filament was significantly less in ketamine groups in 3 trials (31, 35, 41) . The clinical implication of the area of hyperalgesia is poorly understood and not well studied. It is an indicator of central sensitization, and a reduction in the area of hyperalgesia could be a measure of the prevention of central sensitization by ketamine. Interestingly, the reduction in the area of hyperalgesia was not associated with improvement in acute postoperative pain outcome measures in any of the three studies. However, wind-up pain at 7 days was evaluated by Stubhaug et al. (35) and was reduced by ketamine. De Kock et al. (41) evaluated chronic persistent pain by a standardized telephone questionnaire regarding the nature and duration of pain and the analgesic requirements at 2 wk, 1 mo, 6 mo, and 1 yr after surgery. Patients who received IV ketamine had significantly reduced longterm pain. All patients studied by De Kock et al. (46) had undergone surgery for rectal adenocarcinoma. Thus, small dose ketamine may have a role in reducing pathological pain, which is chronic and neuropathic, even without any effect on acute nociceptive pain. Surgical procedures such as thoracotomy and amputation are associated with chronic postoperative neuropathic pain (67) (68) (69) . These may be the ideal patient groups for studying the long-term effects of adding ketamine to opioid analgesia.
Cancer patients with chronic opioid intake develop tolerance and adverse effects. Ketamine has proved to be a useful adjuvant for the management of pain in these patients (70 -72) . However, the usefulness of ketamine in the management of acute postoperative pain in chronic opioid-tolerant patients has never been studied. Patients with chronic opioid intake for pain commonly undergo back surgery and amputation of extremities. This is an area of future research where ketamine may be useful for its opioid-sparing effect.
The incidences of various central nervous system side effects (dizziness, diplopia, dysphoria, dreams, hallucinations disorientation, strange sensations, light headedness, sleep difficulties, and confusion) in ketamine-treated patients were 18%, 10%, 9%, and 0.7% with IV PCA, IV infusion, IV single dose, and epidural groups. No significant increase was seen compared to patients who did not receive ketamine. A trend toward less PONV was seen in IV ketamine bolus and infusion group patients. These reductions in PONV parallel the decreased opioid consumption and improved analgesia in these groups. Respiratory depression was reported in 9 patients; 5 of them received ketamine plus opioids. As the incidence of narcoticinduced respiratory depression is very small, it is difficult to demonstrate any effect of ketamine. In this review, pruritus was reported as a major side effect (45.6%) of epidural opioids and ketamine did not reduce the incidence of pruritus significantly in these patients.
In conclusion, small dose ketamine has been shown to be a useful and safe additive to standard practice opioid analgesia in 54% of studies. Both systemic and epidural ketamine have shown their beneficial opioidsparing effects. Ketamine should be considered as an additive in the surgical population with large opioid requirements, such as major abdominal surgery. Intravenous ketamine is best used as continuous infusion in these patients. Adding ketamine to PCA morphine has not been found to be useful. In minor surgical procedures, a single dose of ketamine ranging from 0.15-1 mg/kg in addition to opioids may be useful. Despite ketamine's opioid-sparing effects, no reduction in opioid-related side effects such as PONV, pruritus, and respiratory depression could be shown in this review. Small dose ketamine was not associated with increased psychomimetic effects such as hallucinations or excessive sedation. Future clinical trials should focus on high-risk groups for opioid-resistant acute postoperative pain (chronic therapeutic opioid intake, substance abusers, amputations, and back surgeries) and on the influence of small dose ketamine used for acute postoperative pain on long-term pain syndromes (postmastectomy, thoracotomy, and phantom pain).
